Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for NovaBay Pharmaceuticals (NBY) over the last 13 years, with Q3 2025 value amounting to $807000.0.

  • NovaBay Pharmaceuticals' Accumulated Expenses fell 2964.25% to $807000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $807000.0, marking a year-over-year decrease of 2964.25%. This contributed to the annual value of $581000.0 for FY2024, which is 5029.94% down from last year.
  • According to the latest figures from Q3 2025, NovaBay Pharmaceuticals' Accumulated Expenses is $807000.0, which was down 2964.25% from $1.0 million recorded in Q2 2025.
  • Over the past 5 years, NovaBay Pharmaceuticals' Accumulated Expenses peaked at $2.8 million during Q1 2023, and registered a low of $581000.0 during Q4 2024.
  • Over the past 5 years, NovaBay Pharmaceuticals' median Accumulated Expenses value was $1.9 million (recorded in 2021), while the average stood at $1.8 million.
  • As far as peak fluctuations go, NovaBay Pharmaceuticals' Accumulated Expenses soared by 6362.26% in 2022, and later crashed by 5708.52% in 2023.
  • Quarter analysis of 5 years shows NovaBay Pharmaceuticals' Accumulated Expenses stood at $2.1 million in 2021, then surged by 30.21% to $2.7 million in 2022, then tumbled by 57.09% to $1.2 million in 2023, then tumbled by 50.3% to $581000.0 in 2024, then soared by 38.9% to $807000.0 in 2025.
  • Its last three reported values are $807000.0 in Q3 2025, $1.0 million for Q2 2025, and $1.8 million during Q1 2025.